Loading...
XTAI
1734
Market cap187mUSD
Dec 05, Last price  
30.75TWD
1D
-0.81%
1Q
-2.23%
Jan 2017
37.52%
IPO
228.53%
Name

Sinphar Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XTAI:1734 chart
P/E
19.19
P/S
1.86
EPS
1.60
Div Yield, %
3.25%
Shrs. gr., 5y
1.58%
Rev. gr., 5y
5.64%
Revenues
3.15b
+6.33%
1,813,468,0001,822,648,0001,840,266,0002,086,627,0002,577,907,0002,642,145,0002,187,401,0002,133,511,0002,134,163,0002,215,837,0002,394,589,0002,388,452,0002,433,516,0002,856,651,0002,962,934,0003,150,628,000
Net income
305m
-18.78%
131,034,000110,930,00072,229,000121,304,000300,691,000163,393,00013,952,00016,545,00036,726,0008,785,000-147,922,000-172,559,000-204,959,000164,174,000375,170,000304,705,000
CFO
594m
+100.26%
309,944,000261,494,000225,583,000164,449,000297,092,000148,580,000280,533,00087,184,000219,871,00079,502,000-79,486,000146,392,000135,544,000425,298,000296,370,000593,512,000
Dividend
Sep 04, 20241 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. It produces anti-cancer pharmaceuticals, such as injections, solid reagents, and hormone reagents; and tablets, soft gel capsules and powder and canned special nutrient products. The company also offers shampoo, body wash, tonic water, lotions, moisturizers, sunscreen lotions, and serums; and pharmaceutical packaging products, such as eye drop bottles, dry canisters, tablet bottles, and various medical grade plastic containers. In addition, it provides plant extracts and functional foods; and OEM services, such as product design, manufacturing, etc. to manufacturers. The company was founded in 1977 and is headquartered in Yilan City, Taiwan.
URL
http://www.sinphar.com/
IPO date
Oct 17, 2000
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT